



March 31, 2026

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, Vice President
Ryosuke Matsui
(TEL. 03-6214-3600)

**Selected for the Financial Times “High-Growth Companies Asia-Pacific 2026” Ranking
(The only Japanese pharmaceutical company selected; sixth consecutive inclusion)**

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. (“the Company”) has been ranked 379th in the High-Growth Companies Asia-Pacific 2026 ranking, published on March 17, 2026, by the UK-based Financial Times in collaboration with Statista.

In the “Pharmaceuticals” category of this ranking, the Company is the only Japanese company selected and has been included for the sixth time in total. The High-Growth Companies Asia-Pacific ranking is based on an objective assessment of the top 500 companies headquartered in 13 countries across the Asia-Pacific region, selected according to their revenue growth rates between 2021 and 2024.

The Company takes this recognition seriously and, without becoming complacent, will continue to steadily strengthen its business foundation and enhance its corporate value over the medium to long term.

For further details, please refer to the following URL.

[FT ranking: High-growth companies Asia-Pacific 2026](#)